NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer
The National Cancer Institute is testing B7-H3 CAR T cell therapy in patients with refractory small cell lung cancer and extrapulmonary neuroendocrine cancer.
Phase III
National Cancer Institute
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The ongoing trial of B7-H3 CAR T cell therapy represents a significant advancement in the treatment of refractory small cell lung cancer and extrapulmonary neuroendocrine cancer. Its success could redefine treatment protocols and influence competitive dynamics in the oncology market, particularly among CAR T therapy developers.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and patient outcomes, as well as any subsequent partnerships or developments in CAR T therapies targeting B7-H3.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.